Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.

Slides:



Advertisements
Similar presentations
J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.
Advertisements

Intracoronary Autologous Bone-Marrow Cell Transfer after Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial Presented.
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.
Glucose – Insulin – Potassium Study in Patients with ST Elevation Myocardial Infarction without Signs of Heart Failure Presented at American College of.
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
A H Gershlick University Hospital of Leicester UK A H Gershlick University Hospital of Leicester UK AA 2008 Who should we rescue ?
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
Continuous Positive Airway Pressure for Heart Patients with Central Sleep Apnea Presented at American College of Cardiology Scientific Sessions 2005 Presented.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.
Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion CREATE-ECLA - GIK Trial Presented at: American Heart Association.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial Presented at The American College of Cardiology Scientific Session.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Impact of Low-molecular-weight Heparin (Reviparin) on Mortality, Reinfarction, and Stroke in Patients with Acute MI CREATE-ECLA - Reviparin Presented at:
Total Occlusion Study of Canada (TOSCA-2) Trial
The American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. Adnan Kastrati
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Management of ST-Elevation Myocardial Infarction
The European Society of Cardiology Presented by Dr. Saman Rasoul
The American Heart Association
The following slides highlight a report on a presentation at a symposium and the late-breaking trials session at the American College of Cardiology 53rd.
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
European Society of Cardiology 2003
GUSTO-IV ACS GUSTO IV ACS evaluated the safety and efficacy of abciximab given as first line medical therapy in a broad population of patients with non-ST.
Invasive versus conservative treatment in unstable coronary syndromes
AMISTAD II: Study Design
The European Society of Cardiology Presented by RJ De Winter
American Heart Association Presented by Dr. Julinda Mehilli
American College of Cardiology Presented by Dr. Michel R. Le May
ARISE Trial Aggressive Reduction of Inflammation Stops Events
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
European Heart Journal Advance Access
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented by Dr. A. H. Gershlick REACT: 6 month results

www. Clinical trial results.org Repeat Thrombolysis Accelerated tPA or reteplase  n=142 Repeat Thrombolysis Accelerated tPA or reteplase  n=142 Primary Endpoint:  Composite of death, reinfarction, CVA, or severe heart failure at 6 months Primary Endpoint:  Composite of death, reinfarction, CVA, or severe heart failure at 6 months REACT: 6 month results Presented at AHA Acute MI patients with failed thrombolysis aspirin and thrombolytic therapy (60% received streptokinase) within 6 hours of chest pain onset, <50% resolution of ST changes on ECG at 90 minutes 42% anterior infarctions 427 Acute MI patients with failed thrombolysis aspirin and thrombolytic therapy (60% received streptokinase) within 6 hours of chest pain onset, <50% resolution of ST changes on ECG at 90 minutes 42% anterior infarctions Conservative Treatment IV Unfractionated Heparin for 24 hours  n=141 Conservative Treatment IV Unfractionated Heparin for 24 hours  n=141 Rescue PCI Angiography with or without Revascularization  n=144 Rescue PCI Angiography with or without Revascularization  n=144

www. Clinical trial results.org REACT: 6 month results Primary Composite Endpoint at 6 Months (Death, MI, CVA, or severe heart failure) Primary Composite Endpoint at 6 Months (Death, MI, CVA, or severe heart failure) Presented at AHA 2004 The primary composite endpoint of death, MI, CVA or severe heart failure at 6 months was significantly lower in the rescue PCI group compared with either the repeat thrombolysis group or the conservative management group Repeat Thrombolysis Repeat Thrombolysis Rescue PCI Conservative Management Conservative Management p<0.001 p=0.002

www. Clinical trial results.org Presented at AHA 2004 Freedom from revascularization was significantly higher in the rescue PCI group compared with the repeat lysis group or the conservative group (overall p=0.05). Minor bleeding was significantly higher in the rescue PCI group (p<0.001), however, major bleeding did not significantly differ among groups. Freedom from Revascularization Minor Bleeding Events REACT: 6 month results Repeat Thrombolysis Repeat Thrombolysis Rescue PCI Rescue PCI Conservative Management Conservative Management Repeat Thrombolysis Repeat Thrombolysis Rescue PCI Rescue PCI Conservative Management Conservative Management

www. Clinical trial results.org Among patients with acute MI and failed reperfusion after thrombolytic therapy, treatment with rescue angiography was associated with a reduction in the primary composite endpoint of death, reinfarction, CVA, or severe HF at 6 months compared with both repeat thrombolysis or conservative management. These six month results reiterate the trial’s preliminary 30-day results presented at the TCT meeting earlier this year. The secondary positive endpoint of freedom from revascularization was also significantly higher in the rescue angiography group compared with either the thrombolytic or conservative management group However, minor bleeding rates were significantly higher in the rescue PCI group The REACT results support the results of the earlier, smaller RESCUE trial, which showed a trend toward lower death and heart failure with rescue PCI compared with conservative management. On the other hand, these results disagree with those of the recent MERLIN trial, which showed no difference between rescue angiography and conservative treatment strategies at 30 days. Hypotheses offered to explain the opposing outcomes of MERLIN and REACT include differences in initial thrombolysis (↑ streptokinase in MERLIN), concomitant medications (↑ GP IIb/IIIa inhibitors in REACT), and inclusion criteria (↑ time to rescue PCI in MERLIN) Among patients with acute MI and failed reperfusion after thrombolytic therapy, treatment with rescue angiography was associated with a reduction in the primary composite endpoint of death, reinfarction, CVA, or severe HF at 6 months compared with both repeat thrombolysis or conservative management. These six month results reiterate the trial’s preliminary 30-day results presented at the TCT meeting earlier this year. The secondary positive endpoint of freedom from revascularization was also significantly higher in the rescue angiography group compared with either the thrombolytic or conservative management group However, minor bleeding rates were significantly higher in the rescue PCI group The REACT results support the results of the earlier, smaller RESCUE trial, which showed a trend toward lower death and heart failure with rescue PCI compared with conservative management. On the other hand, these results disagree with those of the recent MERLIN trial, which showed no difference between rescue angiography and conservative treatment strategies at 30 days. Hypotheses offered to explain the opposing outcomes of MERLIN and REACT include differences in initial thrombolysis (↑ streptokinase in MERLIN), concomitant medications (↑ GP IIb/IIIa inhibitors in REACT), and inclusion criteria (↑ time to rescue PCI in MERLIN) REACT: Summary